| 郭强 李国强 李惊涛 翟海程 郭世文.地喹氯铵联合紫杉醇注射液对神经胶质瘤患者血清IL-6, Th17 细胞水平
及临床疗效的影响[J].,2016,16(33):6522-6525 |
| 地喹氯铵联合紫杉醇注射液对神经胶质瘤患者血清IL-6, Th17 细胞水平
及临床疗效的影响 |
| Effect of DequaliniumChloride Combined with Paclitaxel Injection on theSerumIL-6, Th17 Cell Level and Clinical Curative Effect of Glioma Patients* |
| |
| DOI： |
| 中文关键词: 地喹氯铵 紫杉醇注射液 神经胶质瘤 IL-6 Th17 |
| 英文关键词: Dequaliniumchloride Paclitaxel Injection Glioma IL-6 Th17 |
| 基金项目:陕西省自然科学基金项目(2011JM0913) |
|
| 摘要点击次数: 727 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨地喹氯铵联合紫杉醇注射液对神经胶质瘤患者血清IL-6、Th17 细胞水平及临床疗效的影响。方法：回顾性研究我
院神经胶质瘤患者60 例，根据电脑生成的随机数字表将所有患者随机分为实验组与对照组，每组各30 例，对照组患者给予地喹
氯铵进行治疗，实验组患者在对照组的基础上给予紫杉醇注射液。比较治疗前后两组患者血清IL-6，Th17 细胞水平，并对两组患
者不良反应发生率及临床总有效率进行统计。结果：与治疗前相比，两组患者治疗后的血清IL-6、Th17 细胞水平均显著降低(P＜
0.05)；且与对照组相比，实验组患者血清IL-6、Th17 细胞水平均较低(P＜0.05)。与对照组相比，实验组患者的不良反应发生率较低
(P＜0.05)；临床总有效率较高(P＜0.05)。结论：地喹氯铵联合紫杉醇注射液能够显著提高神经胶质瘤患者临床疗效，降低不良反应
发生率，其机制可能与降低血清IL-6及Th17 细胞水平有关。 |
| 英文摘要: |
| Objective:To investigate the effect of dequalinium chloride combined with Paclitaxel Injection on the serum IL-6,
Th17 cell levels and clinical curative effect of glioma patients.Methods:60 glioma patients fromour hospital were selected and randomly
divided into the control group and the experiment group with 30 cases in each group. The control group was treated by Dequalinium
chloride and the experiment group was treated on the basis of control group with Paclitaxel Injection. The serum IL-6，Th17 cell levels,
incidence of adverse reactions and clinical total effective rate were compared before and after treatment.Results:Compared with before
treatment, the serum IL-6 and Th17 cell levels were significantly decreased after treatment (P＜0.05), and compared with the control
group, the serumIL-6 and Th17 cell levels were lower in the experiment group(P＜0.05). Compared with the control group, the incidence
of adverse reactions was lower (P<0.05), the clinical total effective rate was higher (P<0.05).Conclusion:Dequalinium chloride combined
with Paclitaxel injection could increase the clinical efficacy and reduce the incidence of adverse reactions of glioma patients, it
might be related to the decrease of serumIL-6 level and Th17 cells. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
